Revvity (RVTY) recently introduced new lab automation tools at the SLAS2026 conference, influencing its stock valuation. Despite a recent share price increase, the stock and its P/E ratio are being evaluated against the North American Life Sciences industry average. Analysts suggest Revvity is currently undervalued, with a fair value estimate of US$114.63, driven by expected margin expansion and a shift towards higher-margin offerings.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Assessing Revvity (RVTY) Valuation After New SLAS2026 Lab Automation Launches
Revvity (RVTY) recently introduced new lab automation tools at the SLAS2026 conference, influencing its stock valuation. Despite a recent share price increase, the stock and its P/E ratio are being evaluated against the North American Life Sciences industry average. Analysts suggest Revvity is currently undervalued, with a fair value estimate of US$114.63, driven by expected margin expansion and a shift towards higher-margin offerings.